Hamilton Locke advises MedAdvisor on strategic joint venture with Asian healthcare giant

Hamilton Locke is delighted to have acted for MedAdvisor Limited (ASX: MDR) on the formation of its Singapore-based joint venture with Zuellig Pharma Holdings Pte. Ltd, which is one of Asia’s largest healthcare services groups with over US$13 billion in annual turnover. MedAdvisor is Australia’s leading digital medication management company and offers a world class medication management platform focused on addressing the gap and burden of medication adherence.

The joint venture is focused on commercialising MedAdvisor’s medication management platform across Asia, including in the Philippines and Malaysia. It is expected to help up to 150 million patients with their medication management.

Hamilton Locke advised MedAdvisor on the subscription agreement and shareholders agreement with Zuellig Pharma, on the licencing arrangements under which MedAdvisor exclusively licences its medication management products and technology solutions to the joint venture and on the promotion agreement with Zuellig Pharma which will see Zuellig Pharma market the medication management products to its network of 350,000 pharmacies and medical clinics across Asia.

Hamilton Locke’s team was led by managing partner Nick Humphrey and senior associate Joshua Bell and assisted by lawyer Stephen Vrettos.

Commenting on the transaction, Nick Humphrey said that “Hamilton Locke is proud to have advised MedAdvisor on their strategic partnership with Zuellig Pharma, which is another major step in MedAdvisor’s exciting journey since launching in 2013.”

About Hamilton Locke

Hamilton Locke is a law firm specialising in complex corporate finance transactions, including mergers and acquisitions, private equity, distressed investing and special situations, capital markets and alternative financing.